enGene Holdings Inc. (ENGN)

Market Cap	604.87M
Revenue (ttm)	n/a
Net Income (ttm)	-117.30M
Shares Out	66.98M
EPS (ttm)	-2.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,186
Open	9.16
Previous Close	8.95
Day's Range	8.62 - 9.16
52-Week Range	2.65 - 11.14
Beta	-0.27
Analysts	Buy
Price Target	22.71 (+151.5%)
Earnings Date	Dec 22, 2025

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN
• Website: https://www.engene.com

Analyst Summary

According to 7 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $22.71, which is an increase of 151.50% from the latest price.

Price Target

$22.71

(151.50% upside)

Analyst Consensus: Buy